Related Experiment Video
Updated: Jul 23, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future
Rebecca Kringel1, Katrin Lamszus1, Malte Mohme1
1Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Abstract:
Glioblastoma (GBM) is a highly aggressive primary brain tumor that is largely refractory to treatment and, therefore, invariably relapses. GBM patients have a median overall survival of 15 months and, given this devastating prognosis, there is a high need for therapy improvement. One of the therapeutic approaches currently tested in GBM is chimeric antigen receptor (CAR)-T cell therapy. CAR-T cells are genetically altered T cells that are redirected to eliminate tumor cells in a highly specific manner. There are several challenges to CAR-T cell therapy in solid tumors such as GBM, including restricted trafficking and penetration of tumor tissue, a highly immunosuppressive tumor microenvironment (TME), as well as heterogeneous antigen expression and antigen loss. In addition, CAR-T cells have limitations concerning safety, toxicity, and the manufacturing process. To date, CAR-T cells directed against several target antigens in GBM including interleukin-13 receptor alpha 2 (IL-13Rα2), epidermal growth factor receptor variant III (EGFRvIII), human epidermal growth factor receptor 2 (HER2), and ephrin type-A receptor 2 (EphA2) have been tested in preclinical and clinical studies. These studies demonstrated that CAR-T cell therapy is a feasible option in GBM with at least transient responses and acceptable adverse effects. Further improvements in CAR-T cells regarding their efficacy, flexibility, and safety could render them a promising therapy option in GBM.
Insights
Chimeric antigen receptor (CAR)-T cell therapy shows promise for glioblastoma (GBM), a deadly brain cancer. While challenges like tumor penetration and immunosuppression exist, CAR-T cells offer a feasible treatment with potential for improvement.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cellular Therapy
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis and limited treatment options.
- Current treatments for GBM have a median survival of only 15 months, highlighting the urgent need for novel therapeutic strategies.
- Chimeric antigen receptor (CAR)-T cell therapy represents a promising investigational approach for GBM.
Purpose of the Study:
- To evaluate the feasibility and efficacy of CAR-T cell therapy in treating glioblastoma.
- To identify challenges and limitations associated with CAR-T cell therapy in the context of solid tumors like GBM.
- To explore potential targets and future directions for improving CAR-T cell therapy in GBM.
Main Methods:
- CAR-T cells are genetically engineered T cells designed to target and eliminate tumor cells.
- Studies have investigated CAR-T cells targeting various GBM antigens, including IL-13Rα2, EGFRvIII, HER2, and EphA2.
- Preclinical and clinical studies assessed CAR-T cell therapy's safety, efficacy, and tumor infiltration in GBM models and patients.
Main Results:
- CAR-T cell therapy has demonstrated feasibility in GBM treatment.
- Transient responses and acceptable adverse effects were observed in studies.
- Challenges include restricted tumor trafficking, immunosuppressive tumor microenvironment, antigen heterogeneity, and CAR-T cell safety concerns.
Conclusions:
- CAR-T cell therapy is a viable option for glioblastoma, showing initial promise.
- Overcoming challenges related to efficacy, safety, and manufacturing is crucial for broader clinical application.
- Further advancements in CAR-T cell design and delivery could establish it as a key therapy for GBM.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
